5 units · 21 chapters
The cerebrum comprises 83% of the brain, including both right and left hemispheres, separated by the central sulcus. It contains 52 distinct regions known as Brodmann's areas.
The left hemisphere controls most functions of the right side of the body and is dominant in most people (example: the left hemisphere primarily controls writing for a right-handed person). The right hemisphere controls most functions of the left side of the body and is responsible for understanding facial expressions and emotions.
Each hemisphere contains four major lobes that work interactively, each with distinct functions: the frontal lobe (critical thinking and decision-making), parietal lobe (sensory information from touch and spatial awareness), temporal lobe (auditory information and memory formation), and occipital lobe (interpreting visual information).
The frontal lobe is the largest and most developed lobe and plays a vital role in advanced cognitive processes, such as solving a complex puzzle or creating a detailed plan for future actions.
Functions of the frontal lobe include working memory, reasoning, planning, prioritizing, sequencing behaviors, insight, flexibility, and judgment.
Language (Broca's area): the frontal lobe is responsible for expressive speech. People with Broca's aphasia have damage that primarily affects the frontal lobe. Aphasia is associated with the prefrontal cortex.
Personality: the frontal lobe is the critical region for personality development. Frontal lobe issues affect social skills, and a tumor here can cause behavioral problems. A patient with frontal lobe injury might show changes in speech, reasoning, insight, judgment, and impulse control, causing shifts in personality and emotional responses.
Relationship to dementia: patients with dementia often exhibit changes in frontal lobe functioning, leading to alterations in personality, emotional state, and intellectual capacity, such as struggling to maintain coherent conversations or make sound judgments.
Primary auditory area: processes auditory information from both ears (identifying a siren from an ambulance).
Language (Wernicke's area): receptive speech and language comprehension. Mnemonic: "Wernicke's for Word comprehension."
Memory: stores long-term, episodic, and declarative memories. Emotions: processing emotional responses, attachment, and social behavior.
Auditory hallucinations — hearing sounds or voices not present in reality (patients with schizophrenia may hear non-existent voices). Receptive (Wernicke's) aphasia — inability to comprehend spoken and written language even when speech is clear. Mnemonic: "APHASIA = All People Have A Serious Issue with Aphasia." Amnesia (anterograde or retrograde) — trouble forming new memories or recalling past events after brain injury.
Cerebrovascular accidents can produce altered perception of inputs (unable to differentiate hot and cold), unresponsiveness (diminished consciousness or coma), and sleep-wake cycle alterations (insomnia or excessive daytime sleepiness).
The primary visual cortex is the hub of vision processing: reception and analysis of visual information and coordination with other sensory inputs for meaningful interpretation.
Visual field defects: Hemianopia is loss of half the field of view in each eye, often due to stroke or tumor (the patient sees only half of an object). Quadrantanopia is loss of a quarter of the field of view, caused by damage to specific parts of the visual cortex.
Blindness: total loss of vision from severe damage to the primary visual cortex.
Visual hallucinations: simple hallucinations (geometric shapes, colors, patterns) relate to migraines or drug use; complex hallucinations (lifelike people or animals) are associated with Parkinson's disease and Lewy body dementia. Visual hallucinations are associated with Lewy body dementia.
Primary sensory area: processes sensory information from the body (feeling the warmth of a cup of coffee). Also involved in taste, reading, and writing.
Sensory-perceptual disturbance: difficulty interpreting sensations accurately (misinterpreting clothing as something crawling on the skin).
Agnosia: inability to recognize or interpret sensory information (touching a pen but unable to recognize it by touch alone).
Stereognosis abnormality: difficulty identifying objects without sight (holding keys but unable to identify them by touch).
The Clock Drawing Test (CDT) is a quick and effective tool to screen for neurological issues such as Alzheimer's disease and other dementias. It is an efficient screening method for dementia, completed in under 2 minutes.
Performance impairment on the CDT indicates damage to the right parietal lobe (right hemisphere). If the patient cannot do it, the problem is probably in the RIGHT side of the brain.
Administration: ask the patient to draw a clock with all the numbers and set the time to 10 past 11. Check whether numbers and hands are placed accurately. Struggling or failing to draw certain elements may indicate cognitive impairment related to dementia.
The limbic system regulates and modulates emotions and memory.
Key roles in regulatory functions include appetite, hunger, thirst, water balance, circadian rhythms, body temperature, libido, and hormonal regulation.
Sensory relay center for every sense except smell; modulates memory and related behaviors. Imagine it as a "sensory switchboard" connecting all senses but smell.
Regulates memory, converting short-term into long-term memory. Responsible for motivation, stress management, emotions, and learning. Mnemonic: "Bighead" (big head = memory).
Check on learning: the hippocampus is responsible for short-term to long-term memory, emotions, stress, and learning.
Modulates mood, emotional memories, fear, anxiety, emotions, and aggression. Regulates smell by connecting it to emotions. Mnemonic: "EMOgdala" (EMO = emotional). "FEAR of Smells" = Fear, Emotions, Aggression/Anxiety, Regulates mood and smell.
Check on learning: the amygdala's functions are fear, anger, anxiety, aggression, and stress.
| # | Nerve | Function | Memory image |
|---|---|---|---|
| I | Olfactory | Smell | Fresh onions |
| II | Optic | Vision | Old observant owl |
| III | Oculomotor | Eye movement, pupil constriction | Mount Olympus with rapidly moving eyes |
| IV | Trochlear | Eye movement (superior oblique) | Tall tower peering downward |
| V | Trigeminal | Facial sensation, mastication | Top half of face feeling and chewing |
| VI | Abducens | Eye movement (lateral rectus) | Eyeball stretching horizontally |
| VII | Facial | Face muscle control, taste, tears, saliva | Fish with human facial expressions |
| VIII | Vestibulocochlear | Hearing, balance | Tightrope walker listening to music |
| IX | Glossopharyngeal | Taste, swallowing, saliva | German bakery |
| X | Vagus | Autonomic functions, swallowing, speech | Protective guard |
| XI | Accessory | Shoulder and neck movement | Acrobat with strong neck |
| XII | Hypoglossal | Tongue movement | Frog hopping, catching insects with its tongue |
Cranial nerve XII — "stick out your tongue."
Atypical antipsychotics are characterized by their 5HT2A (serotonin) receptor antagonism. This is the key difference between typical and atypical agents.
Hyperactivity of dopamine in the mesolimbic pathway modulates positive psychotic symptoms. Antagonism of D2 receptors in the mesolimbic pathway treats hallucinations and delusions.
Decreased dopamine in the mesocortical projection is postulated to be responsible for negative and depressive symptoms of schizophrenia, such as lack of motivation and emotional withdrawal.
Modulates motor movement. Dopamine blockade here leads to increased acetylcholine levels. Blockade of D2 in this pathway leads to extrapyramidal symptoms (EPS) such as dystonia, parkinsonism, and akathisia. Long-term D2 blockade can cause tardive dyskinesia and involuntary facial movements.
Parkinson's disease is characterized by degeneration of dopaminergic neurons in the nigrostriatal pathway, which connects the substantia nigra with the striatum.
Blockade of D2 receptors in this pathway increases prolactin levels. Higher prolactin may cause amenorrhea, galactorrhea, sexual dysfunction, gynecomastia, or osteoporosis — for example, a patient on an antipsychotic experiencing decreased libido or irregular menstruation.
Symptoms: muscle spasms of the face, neck, tongue; stiff neck; subjectively painful; facial grimacing. A patient who suddenly develops a twisted neck may be experiencing acute dystonia.
Misconceptions: can be mistaken for agitation or stereotypical movements of schizophrenia.
Unique presentation: oculogyric crisis — prolonged involuntary upward deviation of the eyes bilaterally, which can lead to permanent injury.
Treatment: Cogentin (benztropine).
Symptoms: restlessness, pacing, difficulty standing still, feet constantly in motion, rocking. A patient who cannot sit still during a session may have akathisia.
Misconception: can be mistaken for increased anxiety.
Assessment tools: Barnes Akathisia Rating Scale and Extrapyramidal Symptoms rating scales.
Symptoms: absence of movement, difficulty initiating motions, subjective lack of motivation to move. A patient accused of being lazy might suffer from akinesia.
Treatment: Cogentin (benztropine).
Symptoms due to D2 blockade mimic Parkinson's disease: muscle rigidity, shuffling gait, motor slowing, mask-like facial expression, pill-rolling, and finger tremors.
Misconception: mask-like facies can be confused with affective blunting or flattening.
Treatment: Cogentin (benztropine).
Symptoms: involuntary abnormal movements of the mouth, tongue, face, and jaw; may progress to limbs — persistent tongue protrusion and rolling, lip-smacking and sucking, facial dystonia.
Onset: can take 1–2 years, or occur acutely during initiation, or as a chronic condition at any point in treatment.
Treatment: reduce the dose or change the medication; FDA-approved treatments are Austedo (deutetrabenazine) and Ingrezza (valbenazine).
Warning: Cogentin (benztropine) is contraindicated in tardive dyskinesia.
Note: Reglan (metoclopramide) can cause EPS-like tardive dyskinesia and pseudo-parkinsonian symptoms.
Pharmacokinetics is the study of what the body does to a drug: Absorption, Distribution, Metabolism, and Excretion (ADME).
Absorption: the drug moves into the body; with oral agents this occurs in the small intestine. Distribution: depends on the patient's condition, drug type, and route; affected by the amount of muscle and fat. Metabolism: the drug is broken down for elimination. Excretion: substances leave the body via feces, urine, and skin.
First-pass effect: substrates are significantly reduced by cytochrome P450 (CYP450) enzymes in the liver after enteric absorption. Non-enteric routes bypass the first-pass effect.
Half-life: time needed to clear 50% of the drug from plasma. Steady state is achieved in five half-lives, and five half-lives are required to eliminate a drug.
Inducers speed up metabolism, decreasing the serum level of the drug. Example: polycyclic aromatic hydrocarbons in tobacco smoke induce CYP1A2, accelerating metabolism of clozapine and olanzapine and lowering blood levels. Blood levels of clozapine and olanzapine can rise significantly within days of quitting or reducing cigarettes.
Inhibitors slow metabolism, increasing serum levels and the risk of toxicity.
2C19: reduced activity in 20% of Asians and 19% of African Americans. 1A2: inhibited by SSRIs and induced by cigarette smoking, affecting olanzapine elimination. 2D6: Caucasians are often poor metabolizers; fluoxetine, paroxetine, and bupropion are strong inhibitors. 3A4: inhibited by SSRIs; induced by carbamazepine, impacting oral contraceptive levels.
Inducers cause low serum levels. Inhibitors cause high serum levels. Smoking is a strong inducer — smokers may need higher doses; if they stop smoking, serum levels will increase. Continually assess smoking status to adjust medication.
Age: young children have rapid metabolism (lower drug concentrations); older people have slower metabolism (higher risk of toxicity). Elderly factors: decreased intracellular water and protein binding, low muscle mass, reduced metabolism, increased body fat.
Liver disease inhibits enzymes and increases toxicity risk (first-pass effect). Renal insufficiency elevates serum concentrations due to reduced GFR; NSAIDs, ibuprofen, thiazides, and ACE inhibitors (lisinopril) may heighten serum concentrations of renally excreted drugs such as lithium.
Nutritional status: low muscle mass, reduced protein, and increased fat stores increase drug concentration and toxicity risk. Intracellular volume: reduced in the elderly but increased in pregnancy, potentially requiring dose adjustments.
Pharmacodynamics studies drug action on the body — how drugs interact with receptors, ion channels, and enzymes. Pharmacodynamics = what the drug does to your body. An increase in neurotransmitter action at the synaptic cleft can improve neuron communication. Combining SSRIs, NSAIDs, aspirin, and protein carriers may increase the risk of bleeding.
Agonist: activates a receptor to produce a biological response (morphine mimics endorphins at opioid receptors). Partial agonist: binds but does not fully activate, producing a muted response (buprenorphine, useful in opioid dependence). Inverse agonist: binds the same receptor but induces the opposite response (benzodiazepine-receptor inverse agonists cause anxiety and convulsions). Antagonist: blocks the receptor, preventing endogenous agonists from acting (naloxone reverses opioid overdose).
Ion channel blockers: block sodium, potassium, calcium, or chloride channels. Depolarization requires influx of sodium and calcium (excitatory); repolarization requires outflow of chloride and potassium (inhibitory) — myocardial contractility is inhibited when serum potassium is sufficiently elevated.
Enzyme inhibitors: slow or stop enzyme catalysis so neurotransmitter remains in circulation (MAOIs reduce breakdown of serotonin, norepinephrine, and dopamine). Reuptake inhibitors: block the transport protein, raising neurotransmitter concentration in the synaptic cleft.
Effects: increases well-being and satiety, reduces pain perception. Produced in the raphe nuclei of the brainstem (associated with sleep and mood). Think "Serene-tonin."
Pathology: increased → serotonin syndrome; decreased → depression, obsessive-compulsive disorder, anxiety.
Effects: increases sense of well-being and satiety, decreases hunger and cravings. Produced in the substantia nigra, nucleus accumbens, and ventral tegmental area (associated with motor movement). Mnemonic: "Very Tired Addict" for dopamine's role in addiction and reward.
Pathology: increased → psychosis; decreased → Parkinson's disease, anhedonia, addiction.
Effects: increases heart rate, alertness, and well-being; decreases pain sensitivity. Produced in the locus coeruleus and medullary reticular formation. The "fight or flight" neurotransmitter.
Pathology: increased → anxiety; decreased → depression.
Synthesized in the basal nucleus of Meynert; the parasympathetic neurotransmitter.
Effects: ↓ heart rate (M2); ↑ secretions and salivation (M3); ↑ sweating; ↑ GI motility; ↑ memory and attention; ↑ muscle contraction (nicotinic).
Pathology: relative ↑ ACh → parkinsonism; ↓ ACh → Alzheimer's disease and dementia.
In Parkinson's disease, ↓ dopamine produces a relative ↑ ACh activity in the basal ganglia, contributing to tremor and rigidity — which is why anticholinergics (benztropine, trihexyphenidyl) are used for tremor.
Decreased ACh → dementia, especially Alzheimer's disease and Lewy body dementia (cholinergic deficit) — which is why donepezil, rivastigmine, and galantamine are used.
Most abundant inhibitory neurotransmitter; increases sleepiness; decreases anxiety, alertness, memory, and muscle tension. Mnemonic: "GABA Gab" for its calming effect.
Pathology: decreased → anxiety. Benzodiazepines bind GABA receptors to potentiate the anxiolytic (calming) effects of GABA.
Most abundant excitatory neurotransmitter; increased glutamate increases anxiety ("Glute-tensed").
Pathology: increased → psychosis, mood lability, seizures; decreased → impaired memory, negative symptoms.
Note: increased corticotropin-releasing hormone in the amygdala, hippocampus, and locus coeruleus increases anxiety symptoms.
Therapeutic range 0.6–1.2 mEq/L; toxicity can occur at 1.5 mEq/L or higher. Lithium has a low therapeutic index. It is the standard treatment for manic episodes, reduces suicidal ideation and behavior, and is neuroprotective in bipolar disorder.
Thyroid panel (TSH) — lithium may mimic or cause thyroid dysfunction. Serum creatinine (0.6–1.2 mg/dL) — reflects kidney function. Blood urea nitrogen (10–20 mg/dL). Pregnancy test (hCG). ECG for clients over 50 years old.
Hypothyroidism, weight gain, CNS effects, fine hand tremor (expected), fatigue, mental confusion, headaches, nystagmus, maculopapular rash, pruritus, acne. GI: diarrhea, vomiting, cramps, anorexia. Renal: nephrogenic diabetes insipidus, polyuria, polydipsia, edema, microscopic tubular changes. Cardiac: T-wave inversion, dysrhythmia. Hematologic: leukocytosis.
Signs of toxicity: severe nausea and vomiting, diarrhea, confusion and drowsiness, blurred vision and slurred speech, muscle weakness and ataxia, and coarse hand tremors (coarse tremor is a toxicity sign, fine tremor is not).
Action: immediately stop lithium and check levels.
Lithium levels increase with prostaglandin inhibitors such as NSAIDs. Exceptions: aspirin and acetaminophen do not affect lithium levels. Thiazide diuretics and ACE inhibitors reduce renal clearance and raise levels. Avoid lithium monotherapy in rapid-cycling patients.
Black box warning: hepatotoxicity and pancreatitis. Monitor liver function tests regularly. Mnemonic: "VALue your LIVER."
More effective than lithium for rapid cycling and mixed bipolar episodes — "Rapid VALue."
Therapeutic range 50–125 mcg/mL — "50–125 keeps you alive."
Possible fetal abnormalities if taken in the first trimester: neural tube defects (spina bifida) — "VPA closes the case, but not the neural tube"; cleft lip and cleft palate; cognitive impairment ("VPA IQ drop").
Counsel female patients of childbearing potential about alternative medications or effective birth control if valproic acid is necessary.
Black box warning: agranulocytosis (decreased white blood cells) and aplastic anemia — pallor, fatigue, headache, fever, nosebleeds, bleeding gums, skin rash, shortness of breath.
Stevens-Johnson syndrome, particularly in Asian individuals — screen for the HLA-B*1502 allele before initiating.
3A rules: Aplastic anemia · Asian (Stevens-Johnson) · Agranulocytosis.
Always check pregnancy status (hCG, ages 12–50). Add folic acid 0.4–0.8 mg daily to support neural tube development.
Therapeutic range 4–12 mcg/mL. Carbamazepine is a liver enzyme inducer and may decrease efficacy of oral contraceptives and warfarin. CNS effects: dizziness, drowsiness, ataxia. Hyponatremia — monitor sodium periodically.
Lamictal is used for bipolar depression — effective for acute episodes and preventing bipolar mood episodes.
Black box warning: Stevens-Johnson syndrome (severe rash). Primary action: discontinue lamotrigine immediately at the first sign.
Key signs: fever, sore throat, facial swelling, tongue rash, skin sloughing. Prodromal headache, malaise, arthralgia, and painful mucous membranes may occur before the rash.
Start low (25 mg/day) and titrate gradually over several weeks to avoid severe rash.
Efficacy is reduced with CYP450 inducers (carbamazepine) and enhanced with inhibitors such as valproic acid. Observe closely for mood changes, suicidality, and unusual behavior during initial treatment.
S – Syphilis: tertiary syphilis affecting the brain can present with mania. S – SAM-e: a mood supplement that can induce mania in predisposed individuals. S – Steroids: prolonged prednisone (for asthma or an arthritis flare) can cause mania. S – St. John's Wort / Ginseng in patients with bipolar disorder.
A – Antidepressants in patients with bipolar disorder — an SSRI given for misdiagnosed unipolar depression can trigger mania. I – Isoniazid (tuberculosis therapy). Le – Levothyroxine — excessive dosing produces a hyperthyroid state. D – Disulfiram (Antabuse) — uncommon adverse reaction; also can cause neural tube defects in pregnancy.
Always consider drug-induced mania in new-onset symptoms. Monitor closely when initiating medications known to induce mania, especially in patients with mood disorders. Treat by discontinuing or adjusting the causative agent and consider mood stabilizers or antipsychotics if needed. Educate patients and families about the signs of mania.
Interferon-related depression is often linked to liver disease and its effect on first-pass metabolism, leading to toxic plasma levels (e.g., with ribavirin).
Be aware of medication indications; understand depression risk factors and the biochemical mechanisms linking these medications; monitor patients for depression during treatment.
Risk of neutropenia requires monitoring the absolute neutrophil count (ANC) ONLY, not in conjunction with the white cell count. WBC normal range: 4,500–11,000.
Monitoring schedule: weekly for the first six months; every two weeks for the next six months; then monthly if ANC is normal.
Discontinue clozapine (or carbamazepine) if ANC is less than 1,000/mm³ (neutropenia) or if WBC is between 2,000–3,000 (agranulocytosis risk).
Watch for infection signs: fever, chills, sore throat, weakness — stop the medication at the first sign of infection.
Clozapine may cause increased salivation, seizures, and myocarditis. It is reserved for treatment-resistant schizophrenia or suicidal behavior in schizophrenia or schizoaffective disorder. Smoking cessation can significantly increase clozapine blood levels (CYP1A2).
Olanzapine (Zyprexa) and clozapine are metabolized by CYP1A2, with interaction potential from enzyme inducers such as tobacco and carbamazepine.
Starts smoking → increase olanzapine dose. Stops smoking → decrease olanzapine dose.
Enzyme inducers (tobacco, carbamazepine) decrease substrate levels (subtherapeutic); enzyme inhibitors (clarithromycin, ketoconazole) increase substrate levels.
Two important things to measure on olanzapine: lipid level and abdominal circumference.
Metabolic syndrome — first sign is increased waist circumference; the cluster includes insulin resistance, central obesity, hypertension, hyperglycemia, elevated triglycerides, and low HDL.
Assess for arcus senilis, which can indicate hyperlipidemia and increased heart disease risk, especially in younger adults.
Boosts norepinephrine and dopamine — "Norepinephrine + Dopamine = therapy for Depression."
Contraindicated in seizure disorders, history of seizures, anorexia, or bulimia; bupropion decreases the seizure threshold. Priapism (prolonged erection) is a notable adverse effect.
Sertraline (SSRI): low drug-to-drug interactions — "Selectively Safe among SSRIs" (along with Lexapro).
Clomipramine (TCA): helps with chronic pain but is not as safe as SNRIs — "Clings to pain therapy, but Caution with safety."
NDRIs are specific for depression with low energy and fatigue — "No energy? No problem."
Duloxetine (SNRI): helps with chronic pain — "Dials up serotonin and norepinephrine to Relieve Intense pain."
Remember each medication's contraindications, interactions in combination therapy, side-effect profiles, and dosing/titration schedules.
| Medication | Teratogenic risk | Memory hook |
|---|---|---|
| Benzodiazepines | Floppy baby syndrome, cleft palate | "Benzo" sounds like "bend" — bendable, floppy baby |
| Carbamazepine | Neural tube defects | "Carbs for the brain" |
| Lithium | Ebstein anomaly (congenital heart defect, first trimester); grade 2/5 harsh systolic murmur | "Li-Heart" |
| Divalproex (Depakote) | Neural tube defects, especially spina bifida | "Diva-Neuro" |
Benzodiazepine withdrawal in newborns: irritability, hypertonia, tremors. Carbamazepine is an enzyme-inducing antiepileptic with significant interactions. Lithium requires close serum monitoring and hydration (nephrogenic diabetes insipidus). Divalproex requires routine liver and pancreas monitoring.
A hypertensive crisis occurs when MAOIs are taken with tyramine-containing foods (tyramine is a precursor of norepinephrine) — for example, aged cheese. It is life-threatening and cannot be reversed until the body produces more MAO.
Dangerous co-medications: meperidine, stimulants/sympathomimetics (amphetamines, methylphenidate), decongestants (pseudoephedrine), TCAs, atypical antipsychotics, St. John's Wort, L-tryptophan, and asthma medications (albuterol).
Symptoms: elevated blood pressure, sudden explosive occipital headache, facial flushing, palpitations, pupillary dilation, diaphoresis, fever.
Treatment: stop the MAOI; administer phentolamine (alpha-adrenergic antagonist); stabilize fever with antipyretics or cooling.
Educate patients on a low-tyramine diet and medication avoidance.
Caused by antipsychotics (e.g., haloperidol). Features: extreme muscular rigidity (stiff like a wooden board), mutism, hyperthermia (> 100.4 °F), tachycardia, diaphoresis, altered level of consciousness.
Labs: elevated CPK ("higH C-PeeK-a-boo"), myoglobinuria / rhabdomyolysis (dark urine — "Myo-ROOM-dark urine"), leukocytosis, elevated LFTs ("High Fliers: ALTitude & ASTronauts").
NMS develops rapidly, often within the first two weeks of starting or increasing an antipsychotic.
Always discontinue the offending agent. Bromocriptine (dopamine D2 agonist) — "Bromance with D2." Dantrolene (muscle relaxant) for rigidity — "Dan-t-rocks those rigid muscles."
Distinguish NMS from serotonin syndrome, which is caused by serotonergic agents.
Caused by antidepressants (SSRI, TCA, MAOI, SNRI) — e.g., taking an SSRI and an MAOI together, combining an SSRI with St. John's Wort, or using more than one SSRI.
Key symptoms: hyperreflexia, myoclonic jerks, agitation, restlessness, tachycardia and elevated blood pressure, headache, sweating, shivering, goosebumps, confusion, fever, seizures, unconsciousness.
Treatment: discontinue the offending agent and administer cyproheptadine.
SSRI → MAOI: wait two weeks. Prozac (fluoxetine) → MAOI: wait five weeks. MAOI → SSRI: wait two weeks.
Similarities: both present with fever and altered mental status. Differences: serotonin syndrome = hyperreflexia and myoclonic jerks; NMS = muscle rigidity, mutism, autonomic instability.
Abrupt discontinuation or rapid decrease of serotonin reuptake inhibitors causes: fatigue and lethargy, myalgia, nausea and vomiting, ataxia, impaired memory, agitation. Always taper SSRIs, TCAs, and MAOIs.
Longer treatment duration increases risk; symptoms last days to weeks; monitor during tapering.